Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps
Introduction Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/9/11/e017177.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260066950709248 |
|---|---|
| author | Ravi Retnakaran Caroline K Kramer Lisa Richardson Yaanu Jeyakumar Shohinee Sarma |
| author_facet | Ravi Retnakaran Caroline K Kramer Lisa Richardson Yaanu Jeyakumar Shohinee Sarma |
| author_sort | Ravi Retnakaran |
| collection | DOAJ |
| description | Introduction Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.Methods We searched PubMed/Embase/ClinicalTrials.gov. Prevalence of each racial/ethnic group was compared in relation to the USA, Canada, the UK, Brazil and South Africa. The geographical locations of the trial sites were extracted.Results 27 RCTs were identified (n=21 547 participants). Meta-analyses of prevalence demonstrated the vast predominance of white/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%). The gaps in representation were evidenced by the significantly under-represented proportion of non-white individuals in these RCTs as compared with the prevalence of non-white individuals in the general population of the USA (−23%, p=0.002) and Canada (−34%, p<0.0001), reaching an alarming gap of −58% in relation to Brazil and striking under-representation of −68% as compared with South Africa. Similar discrepancies in proportions of blacks, Asians and Indigenous peoples as compared with reference nations were found. Moreover, the trial sites (n=1859) were predominately located in high-income countries (84.2%), in sharp contrast to the global prevalence of obesity that is predominantly in low-income and middle-income countries.Conclusion There are discrepancies in representation of racialised and ethnically diverse populations in obesity trials as compared with multiethnic populations worldwide. These data highlight the need for broader reform in the research process in order to ultimately address health inequities. |
| format | Article |
| id | doaj-art-021bee6aff9d4f1c802f2f773b2699a9 |
| institution | OA Journals |
| issn | 2059-7908 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj-art-021bee6aff9d4f1c802f2f773b2699a92025-08-20T01:55:42ZengBMJ Publishing GroupBMJ Global Health2059-79082024-11-0191110.1136/bmjgh-2024-017177Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gapsRavi Retnakaran0Caroline K Kramer1Lisa Richardson2Yaanu Jeyakumar3Shohinee Sarma4Mount Sinai Hospital, Toronto, Ontario, CanadaMount Sinai Hospital, Toronto, Ontario, CanadaUniversity of Toronto, Toronto, Ontario, CanadaMount Sinai Hospital, Toronto, Ontario, CanadaUniversity of Toronto, Toronto, Ontario, CanadaIntroduction Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.Methods We searched PubMed/Embase/ClinicalTrials.gov. Prevalence of each racial/ethnic group was compared in relation to the USA, Canada, the UK, Brazil and South Africa. The geographical locations of the trial sites were extracted.Results 27 RCTs were identified (n=21 547 participants). Meta-analyses of prevalence demonstrated the vast predominance of white/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%). The gaps in representation were evidenced by the significantly under-represented proportion of non-white individuals in these RCTs as compared with the prevalence of non-white individuals in the general population of the USA (−23%, p=0.002) and Canada (−34%, p<0.0001), reaching an alarming gap of −58% in relation to Brazil and striking under-representation of −68% as compared with South Africa. Similar discrepancies in proportions of blacks, Asians and Indigenous peoples as compared with reference nations were found. Moreover, the trial sites (n=1859) were predominately located in high-income countries (84.2%), in sharp contrast to the global prevalence of obesity that is predominantly in low-income and middle-income countries.Conclusion There are discrepancies in representation of racialised and ethnically diverse populations in obesity trials as compared with multiethnic populations worldwide. These data highlight the need for broader reform in the research process in order to ultimately address health inequities.https://gh.bmj.com/content/9/11/e017177.full |
| spellingShingle | Ravi Retnakaran Caroline K Kramer Lisa Richardson Yaanu Jeyakumar Shohinee Sarma Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps BMJ Global Health |
| title | Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps |
| title_full | Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps |
| title_fullStr | Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps |
| title_full_unstemmed | Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps |
| title_short | Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps |
| title_sort | representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of glp 1 medicines for obesity a systematic review and meta analysis of gaps |
| url | https://gh.bmj.com/content/9/11/e017177.full |
| work_keys_str_mv | AT raviretnakaran representationofracialisedandethnicallydiversepopulationsinmulticentrerandomisedcontrolledtrialsofglp1medicinesforobesityasystematicreviewandmetaanalysisofgaps AT carolinekkramer representationofracialisedandethnicallydiversepopulationsinmulticentrerandomisedcontrolledtrialsofglp1medicinesforobesityasystematicreviewandmetaanalysisofgaps AT lisarichardson representationofracialisedandethnicallydiversepopulationsinmulticentrerandomisedcontrolledtrialsofglp1medicinesforobesityasystematicreviewandmetaanalysisofgaps AT yaanujeyakumar representationofracialisedandethnicallydiversepopulationsinmulticentrerandomisedcontrolledtrialsofglp1medicinesforobesityasystematicreviewandmetaanalysisofgaps AT shohineesarma representationofracialisedandethnicallydiversepopulationsinmulticentrerandomisedcontrolledtrialsofglp1medicinesforobesityasystematicreviewandmetaanalysisofgaps |